Difei Yang
Stock Analyst at Mizuho
(1.36)
# 2,919
Out of 4,479 analysts
31
Total ratings
30.56%
Success rate
10.23%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $0.96 | +108.33% | 2 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | n/a | $0.92 | - | 2 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | n/a | $16.80 | - | 5 | Jul 30, 2021 | |
| ELOX Eloxx Pharmaceuticals | Initiates: Buy | n/a | $0.73 | - | 1 | Jun 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | n/a | $5.41 | - | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | n/a | $0.74 | - | 3 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | n/a | $4.01 | - | 3 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | n/a | $154.20 | - | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | n/a | $2.06 | - | 1 | Apr 23, 2020 | |
| RVNC Revance Therapeutics | Maintains: Buy | n/a | $2.42 | - | 2 | Apr 1, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | n/a | $1.17 | - | 2 | Feb 3, 2020 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Neutral | n/a | $1.19 | - | 2 | Feb 27, 2019 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $4.30 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | n/a | $10.75 | - | 1 | Feb 13, 2018 | |
| VIVE Viveve Medical | Initiates: Buy | n/a | $0.00 | - | 1 | Nov 17, 2017 | |
| HRTX Heron Therapeutics | Initiates: Buy | n/a | $2.74 | - | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $0.96
Upside: +108.33%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: n/a
Current: $0.92
Upside: -
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: n/a
Current: $16.80
Upside: -
Eloxx Pharmaceuticals
Jun 30, 2021
Initiates: Buy
Price Target: n/a
Current: $0.73
Upside: -
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: n/a
Current: $5.41
Upside: -
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.74
Upside: -
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: n/a
Current: $4.01
Upside: -
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: n/a
Current: $154.20
Upside: -
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: n/a
Current: $2.06
Upside: -
Revance Therapeutics
Apr 1, 2020
Maintains: Buy
Price Target: n/a
Current: $2.42
Upside: -
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.17
Upside: -
Marinus Pharmaceuticals
Feb 27, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $4.30
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: n/a
Current: $10.75
Upside: -
Viveve Medical
Nov 17, 2017
Initiates: Buy
Price Target: n/a
Current: $0.00
Upside: -
Heron Therapeutics
Sep 27, 2017
Initiates: Buy
Price Target: n/a
Current: $2.74
Upside: -